With an option to invest in a rapid diagnostic test for malaria, a multinational venture capital firm required support to uncover risks associated with the investment opportunity.
Working under tight timelines, Shift Health conducted a market analysis of the diagnostic, focusing on key target segments, distribution channels, epidemiological data, competitor products and experience of the company. Based on the research, Shift Health concluded that existing competitors could not be replaced given non-superiority of the new test, and that other viable target markets could potentially be pursued, including at-home use. The size of these markets were calculated and deemed to be limited.
Shift Health flagged critical commercial and technology risks that allowed the client to confidently pass on the opportunity.